Genenta Science Secures €20 Million Convertible Bond to Support Pipeline Expansion

Genenta Science, an Italian biotech company listed on Nasdaq specializing in immuno-oncology and cellular and gene therapies, issued a €20 million convertible bond. The issuance aims to support the expansion of its pipeline for metastatic renal carcinoma and was subscribed by Fondazione ENEA Tech e Biomedical. This foundation manages the Technology Transfer Fund and the Biomedical Industrial Research and Development Fund on behalf of the Ministry of Enterprises and Made in Italy.

Giovannelli e Associati assisted Genenta Science. The team was coordinated by partners Gianvittorio Giroletti Angeli and Andrea Bartolucci and included associates Francesca di Lorenzo for Corporate M&A matters and Santi Marco Calabrò for labor law aspects.

Fondazione ENEA Tech e Biomedical was assisted by Portolano Cavallo. The team was coordinated by partners Alessandro Tanno, head of the Banking & Finance department, and Antonia Verna, along with senior associate Simona Siciliani. They were supported by Gianmarco Casciotta, as well as Tabita Costantino for labor law matters, Francesca Ellena and Chiara Ciapparelli for intellectual property aspects, Elisa Stefanini and Claudio Todisco for regulatory aspects in the healthcare sector, Giulio Novellini and Elena Mandarà for privacy matters, and Ilaria Curti and Gaia Accetta for compliance aspects.

The notarial aspects of the transaction were handled by Studio Notarile Marchetti, represented by notary Andrea De Costa.